CJC-1295 / Ipamorelin — the workhorse GH protocol.

CJC-1295 is a modified GHRH analog with a much longer half-life than Sermorelin (8+ days for CJC-1295 with DAC; ~30 minutes for the no-DAC variant). Ipamorelin is a selective ghrelin receptor agonist that triggers GH release through the secretagogue pathway — importantly, without spiking cortisol or prolactin (a problem that plagued older GHRPs like GHRP-2 and GHRP-6).

The combination hits both upstream GH signaling pathways simultaneously. The result is a meaningfully larger GH pulse than GHRH-only protocols deliver — translating to faster sleep improvements, more visible body-composition response, and better recovery from training within 6–8 weeks.

GH is released from the anterior pituitary in pulses, driven by two upstream signals: GHRH from the hypothalamus and ghrelin / GHS-R activation. CJC-1295 amplifies the first; Ipamorelin amplifies the second. Hitting both pathways at once produces a synergistic GH pulse that's larger than either drug alone can produce.

Ipamorelin's clean receptor profile is what makes this combination clinically useful. Older GHRPs (GHRP-2, GHRP-6) also bind cortisol-releasing receptors, which is why they fell out of favor. Ipamorelin doesn't.

CJC-1295 / Ipamorelin tends to fit:

• Patients prioritizing visible body-composition change
• Athletes managing training-block recovery
• Patients who've responded modestly to Sermorelin and want to step up
• Patients prioritizing deep sleep with metabolic benefits

For first-peptide patients, we often start with Sermorelin to establish tolerance before moving to CJC/Ipa. For patients coming in with prior peptide experience, CJC/Ipa is often the right starting point.

Typical clinical protocols: 100mcg Ipamorelin + 100mcg CJC-1295 (no-DAC variant), subcutaneous injection, 5 nights per week before bed on an empty stomach. The CJC-1295 with DAC variant is dosed less frequently (1–2x/week) due to its much longer half-life.

Vektor primarily prescribes the no-DAC variant because the dose control is more precise and the GH pulse pattern more closely mimics natural pulsatile release.

Most patients report markedly deeper sleep within the first week. Energy, mental clarity, and recovery from training improve in weeks 2–4. Visible body-composition changes (lean mass increase, visceral fat reduction) typically show up at 6–8 weeks of consistent dosing.

IGF-1 re-tested at week 6–8 to confirm physiologic response. Quarterly check-ins thereafter.

Vektor prescribes CJC-1295 / Ipamorelin as a pre-blended 5mL vial through our 503A pharmacy partner — 1.2mg CJC-1295 + 2mg Ipamorelin in solution. One vial covers approximately one month of standard dosing.

This is the most-prescribed peptide in our practice for the patient population that's done their reading. The dual- pathway response is the differentiator most patients are looking for when they search for “CJC-1295 vs Sermorelin.”